Veru Inc., a biopharmaceutical company listed on Nasdaq under the ticker VERU, has released a corporate presentation highlighting its focus on cardiometabolic diseases. The presentation outlines Veru's drug candidate pipeline, emphasizing their work on the Cardiometabolic Obesity Program and the Cardiometabolic Atherosclerosis Program. The company is developing a combination of Enobosarm and GLP-1 receptor agonist for weight loss and maintenance, with Phase 2b results showing positive outcomes. Additionally, Veru is progressing with Sabizabulin, an oral microtubule disruptor aimed at treating inflammation in atherosclerosis patients. The presentation notes the significant nonselective loss of both fat and muscle associated with GLP-1 receptor agonist drugs, particularly affecting older patients with obesity. You can access the full presentation through the link below.